Innovations in CNS Novel therapeutics and future R&D strategies

The CNS drug market presents significant profit opportunities, but also carries high risks for companies aiming to achieve blockbuster status; pipelines based on novel molecular targets to treat underlying disease promise to transform the treatment of psychiatric and neurological diseases, however research and development of these drugs requires an innovative approach to ensure investment is maximized. ‘Innovations in CNS: Novel therapeutics and future R&D strategies’ assesses novel treatments in development for major CNS disorders, comparing them with existing medications in terms of unmet need and forecasting their success in the commercial market. This report will enable you to understand the research tactics of your competitors and develop winning strategies for future growth in the lucrative CNS market. The report provides a survey of the pipelines of all of the major players in the CNS area. Detailed company profiles featured in the report include: AstraZeneca, GlaxoSmithKline, Merck &Co, Pfizer, and Sanofi-Aventis. Use this report to understand the factors that will ensure your product pipeline achieves clinical and commercial success and analyze the product pipelines of the leading companies in the CNS market.

Published: January 2007
Table of Contents
Table of Contents (PDF)
Price: $2,875.00 / GBP1,437.50